AI-generated summary
The authors report a randomized trial of multiwavelength light therapy in 44 people with intermediate non-exudative age-related macular degeneration, comparing active treatment at 590, 660 and 850 nm with sham treatment. They report a statistically significant visual acuity improvement in treated eyes at 9 months, with slower geographic atrophy growth and no safety concerns observed.
- Participants
- 44
- Who or what was studied
- Adults with intermediate stage non-exudative age-related macular degeneration, 44 subjects (53 eyes)
- Wavelengths
- 590, 660, 850 nm
- Limits stated in the abstract
- The abstract reports a between-group visual acuity difference that was not statistically significant and describes the geographic atrophy findings as suggestive of potential effects, without established certainty.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Age-related macular degeneration, Sham, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.